IP Library › Granted Patent US 11,098,103
Granted Patent B2
US 11,098,103 · App. 16/354,689 · Granted Aug 24, 2021

CD80 extracellular domain polypeptides and their use in cancer treatment

Inventors: Thomas Brennan (Cupertino, CA); David Bellovin (San Jose, CA); David Busha (Sausalito, CA); Barbara Sennino (San Francisco, CA)
Assignee: Five Prime Therapeutics, Inc.
C07K14/70532A61K38/1774A61K39/39558A61K45/06C07K16/00C07K16/2803A61K38/00C07K2317/41C07K2319/03C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,098,103
App. No.
16/354,689
Granted
Aug 24, 2021
Kind
B2
Abstract

This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

Claims (8)

1. An isolated polynucleotide comprising a nucleic acid sequence that encodes a CD80 extracellular domain (ECD) fusion molecule comprising the polypeptide sequence of SEQ ID NO:20.

2. The isolated polynucleotide of claim 1 , wherein the nucleic acid sequence further encodes a leader sequence.

3. A vector comprising the polynucleotide of claim 1 .

4. A vector comprising the polynucleotide of claim 2 .

5. A host cell comprising the vector of claim 3 .

6. A host cell comprising the vector of claim 4 .

7. A method of obtaining a CD80 ECD fusion protein comprising isolating the fusion molecule expressed by the host cell of claim 5 .

8. A method of obtaining a CD80 ECD fusion protein comprising isolating the fusion molecule expressed by the host cell of claim 6 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2019
From: HOLDERBAUM, THOMAS
To: HENKEL AG & CO. KGAA
Reel/Frame 048829/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2019
From: BRENNAN, THOMAS; BELLOVIN, DAVID; BUSHA, DAVID; SENNINO, BARBARA
To: FIVE PRIME THERAPEUTICS, INC.
Reel/Frame 048694/0024 →
Continuity (4)
Continuation 15340238 · Nov 1, 2016
Provisional Application 62249836 · Nov 2, 2015
Provisional Application 62373654 · Aug 11, 2016
Related Publication 20190202889A1 · Jul 4, 2019
Cited By (1)
US 12,692,307